Carisma Therapeutics Inc (CARM) concluded trading on Wednesday at a closing price of $0.60, with 36.57 million shares of worth about $21.94 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.48% during that period and on June 11, 2025 the price saw a loss of about -45.66%. Currently the company’s common shares owned by public are about 41.79M shares, out of which, 21.12M shares are available for trading.
Stock saw a price change of 242.73% in past 5 days and over the past one month there was a price change of 212.54%. Year-to-date (YTD), CARM shares are showing a performance of 44.03% which decreased to -44.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.14 but also hit the highest price of $1.90 during that period. The average intraday trading volume for Carisma Therapeutics Inc shares is 12.32 million. The stock is currently trading 136.28% above its 20-day simple moving average (SMA20), while that difference is up 167.33% for SMA50 and it goes to 2.84% higher than SMA200.
Carisma Therapeutics Inc (NASDAQ: CARM) currently have 41.79M outstanding shares and institutions hold larger chunk of about 8.10% of that.
The stock has a current market capitalization of $25.21M and its 3Y-monthly beta is at 2.04. It has posted earnings per share of -$1.22 in the same period. It has Quick Ratio of 1.34. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CARM, volatility over the week remained 92.63% while standing at 39.13% over the month.
Stock’s fiscal year EPS is expected to rise by 50.00% while it is estimated to decrease by -2.33% in next year. EPS is likely to shrink at an annualized rate of 24.74% for next 5-years, compared to annual growth of 42.71% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on December 12, 2024 offering a Neutral rating for the stock and assigned a target price range of between $10 and $1 to it. On April 11, 2024, BTIG Research Initiated their recommendations, while on October 03, 2023, CapitalOne Initiated their ratings for the stock with a price target of $10. Stock get an Outperform rating from Evercore ISI on July 06, 2023.
